Intellectual Property
Leveraging a Novel Drug Discovery Platform
By selectively modifying psychedelic-based scaffolds, Cybin is able to develop new active pharmaceutical ingredients (APIs) and engineer novel next-generation psychedelic-based molecules with the potential for improved safety and bioavailability, and pharmacokinetic profiles and controlled delivery to fully unlock the therapeutic benefits for patients and providers. This approach has been integral to the discovery and development of our lead clinical-stage assets, CYB003, our proprietary deuterated psilocybin analog being evaluated for the treatment of Major Depressive Disorder, and CYB004, our deuterated DMT molecule being evaluated for the treatment of Generalized Anxiety Disorder.
By replacing selective hydrogen atoms with deuterium and optimizing the unique physiochemical attributes of CYB003 and CYB004, we expect to address the shortcomings of native forms of psychedelics.
Advancing Innovative Drug Delivery Systems
Our approach leverages efficient delivery systems that bypass first-pass liver metabolism and provide a direct path to the brain. This approach aims to allow for:
• Fast onset of action;
• Better control of dosing;
• Short duration;
• Low variability;
• Reduced side effects; and
• Less invasive / convenient dosing methods.
Our proprietary delivery systems have broad applicability across many compounds, including both deuterated and non-deuterated psychedelic compounds.
Patents
Cybin has multiple patent filings covering a wide range of novel compounds from different psychedelic classes, including claims to targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.
Cybin’s novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of effect, improved bioavailability by way of bypassing the liver metabolism and more efficient dose control for a better patient experience and optimized therapeutic outcomes.
Patents
Cybin has multiple patent filings covering a wide range of novel compounds from different psychedelic classes, including claims to targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.
Cybin has been granted a composition of matter patent from the USPTO that covers covers composition of matter claims on the NCE-eligible CYB004 active molecule until at least 2041.
The World Intellectual Property Organization (WIPO) has published an international patent application for Cybin covering inhalation delivery methods for multiple psychedelic molecules that are currently being researched and developed by Cybin as well as other psychedelic molecules that may be developed in the future.
We are taking a similar approach to securing the intellectual property position for CYB003. Cybin has filed multiple provisional and non-provisional patent applications around its CYB003 program, including making many international patent filings. Cybin is the first company to evaluate a deuterated psilocybin analog in clinical trials, and continues to work to strengthen its intellectual property position for CYB003 from ongoing and future clinical trials.
Strong IP with International Coverage
Cybin has more than 50 patent filings and applications across 6 patent families spanning 7 research programs
through
a combination of internal and external licensing agreements
PROGRAM
- PROVISIONAL
- INTERNATIONAL (PCT)
- NATIONAL STAGE
- PATENT GRANT
CYB002
Amorphous psilocybin
INTERNATIONAL (PCT)
CYB003
Psilocybin analogs
INTERNATIONAL (PCT)
CYB004
Proprietary Tryptamine derivatives
PATENT GRANT
CYB004
Tryptamines compositions
PROVISIONAL
CYB004
Inhalation delivery methods
INTERNATIONAL (PCT)
CYB004
Combination drug therapies
INTERNATIONAL (PCT)
CYB005
Phenethylamine class A
INTERNATIONAL (PCT)
CYB005
Phenethylamine class B
INTERNATIONAL (PCT)
CYB005
Phenethylamine class C
PROVISIONAL
CYB005
Phenethylamine class D
PROVISIONAL
